News


New Team member

01. September 2021

BGPartner is pleased to welcome attorney at law Maja Rasovic to the Berne team as of September 1, 2021. Further information on Maja Rasovic and our entire team can be found here.


Mergers & Acquisitions

24. August 2021

The Swiss e-commerce agency and software house MySign becomes part of the German Allgeier Group. BGPartner advises and supports MySign in all legal aspects. The team was led by Olivier Bula (Partner) and further composed Oliver Gnehm (Partner), Victoria Marty (Associate), Thomas Gysin (Associate). Click here for the official press release.  


New Team member

01. July 2021

BGPartner is pleased to welcome attorney at law Nathalie Loretan to the Berne team as of July 1, 2021. Further information on Nathalie Loretan and our entire team can be found here.


Exciting Times! We are proud to announce

15. June 2021

Bader Gnehm & Partner AG is now BGPartner AG. With the new name, we are also giving ourselves a new logo and a fresh, more dynamic appearance overall.  

Mastering Law and Negotiation is our guiding principle. We want to be your partner of choice for intelligent solutions in all legal and negotiation matters. We create solution spaces that inspire!

BGPartner – Mastering Law and Negotiation


BGPartner advises series C financing

01. June 2021

BGPartner advises lead investors HBM Healthcare Investments Ltd. and Novo Holdings A/S on CHF 100 mio financing round of Numab Therapeutics Ltd.

HBM Healthcare Investments Ltd and Novo Holdings A/S as co-lead-investors, together with other investors including Forbion and Black Rock, successfully closed an investment in Numab Therapeutics Ltd’s series C financing round, raising a total amount of CHF 100 million.

Numab Therapeutics Ltd is a clinical stage biopharmaceutical company developing next-generation multi-specific antibody-based immunotherapies for cancer and inflammation. The proceeds will support acceleration and expansion of the clinical development of Numab’s lead program NM21-1480 into multiple cancer indications, and the advancement of the company’s pipeline of multi-specific antibodies in oncology and inflammation, into clinical trials.

BGPartner assisted HBM Healthcare Investments Ltd and Novo Holdings A/S in the negotiations and advised them on all Swiss legal matters with regard to the series c financing round. The team was led by Oliver Gnehm (Partner) and further consisted of Olivier Bula (Partner), Victoria Marty (Associate), Thomas Gysin (Associate) and Fabiola Anthamatten (Associate).

BGPartner has been repeatedly awarded as top law firm in the area of "Private Equity and Venture Capital". More information can be found here.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17